mutacin 1140

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2003-2018
0120032018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Lantibiotics offer an untapped pipeline for the development of novel antibiotics to treat serious Gram-positive (+) infections… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2017
2017
Mutacin 1140 belongs to the epidermin group of lantibiotics. Epidermin class lantibiotics are ribosomally synthesized and… (More)
Is this relevant?
Review
2016
Review
2016
The intrinsic qualities of lanthipeptides for their use as therapeutic drugs present several challenges because of their… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 4
  • table 2
Is this relevant?
2014
2014
Lantibiotics are ribosomally synthesized peptide antibiotics composed of an N-terminal leader peptide that promotes the core… (More)
  • figure 1
  • table 1
  • table 2
  • table 2
  • figure 2
Is this relevant?
2010
2010
Mutacin 1140 is produced by Streptococcus mutans and belongs to the type A lantibiotic family. Experiments were done to optimize… (More)
Is this relevant?
2008
2008
Mutacin 1140 and nisin A are peptide antibiotics that belong to the lantibiotic family. N-Terminal rings A and B of nisin A and… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2003
2003
Mutacin 1140 is a member of a family of ribosomally synthesized peptide bacteriocins called lantibiotics (lanthionine-containing… (More)
Is this relevant?